Det var på Q&A på kvartalspresentasjonen for Q3-19 han nevnte Moderna første gang. Usikker på hvem som stilte spørsmålet, men mener å huske at det var @sorlendingen:
«I guess, I can start again, (inaudible). The nucleic acid area is probably one of the hottest, I guess, area within medicine today, maybe the hottest one. You have revealed in the press release yesterday that you have been cooperating with AstraZeneca since 2015. Can you say a little bit about AstraZeneca’s position within that market there?»
Per Walday:
«So yes, AstraZeneca is a big player in that market. They have a collaboration with Moderna, which is one of the important players in mRNA, specifically, and one of the pioneers within mRNA. And what they have of other – we have a confidential agreement. So I’m not sure what’s in the public domain of what I know. So I will be a bit difficult – a bit careful, I mean, with what I say here. But clearly, they are an important player in this field. And I think several of the big pharma companies are now putting some quite big bets on these kind of nucleic acids for the future because it’s a completely new area that opens up a plethora of opportunities where you probably before didn’t have the same kind of opportunities at all. I think that’s all I can say. They are absolutely into this»
PS1: PW dro altså Moderna frem igjen på Radium samme dag, helt uoppfordret.
PS2: Et annet sitat fra PW som er greit å gjenta:
«So yes, I would say that the results are quite encouraging, I would say, quite good results. And we hope that those are – and there shouldn’t be no reason why they shouldn’t be transferable to other areas as well. So from a pure research results perspective, I am quite optimistic, absolutely. But then there are all sorts of strategic evaluations on the other side of here, and we don’t control our partners. So that’s the way it is.»